HLA class-I-peptide stability mediates CD8

Alleles CD8-Positive T-Lymphocytes / immunology Female HEK293 Cells HIV Infections / immunology Histocompatibility Antigens Class I / immunology Humans Immunodominant Epitopes / immunology Peptides / immunology Protein Denaturation Protein Stability Surface Properties
CD8+ T cells HIV HLA epitopes immunodominance vaccine

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
13 07 2021
Historique:
received: 09 11 2020
revised: 24 03 2021
accepted: 18 06 2021
entrez: 14 7 2021
pubmed: 15 7 2021
medline: 9 2 2022
Statut: ppublish

Résumé

Defining factors that govern CD8

Identifiants

DOI: 10.1016/j.celrep.2021.109378 PMID: 34260940 PMC: PMC8293625
pubmed: 34260940
pii: S2211-1247(21)00776-2
doi: 10.1016/j.celrep.2021.109378
pmc: PMC8293625
pii:
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Immunodominant Epitopes 0
Peptides 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109378

Subventions

Organisme : NIAID NIH HHS
ID : DP2 AI154421
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI144462
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI149704
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM118166
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIDDK NIH HHS
ID : P01 DK011794
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests E.J.R., B.D.W., and G.D.G. have filed patent application PCT/US2020/022403.

Références

J Immunol. 2007 Jun 15;178(12):7890-901
pubmed: 17548627
Cell. 2020 Oct 29;183(3):818-834.e13
pubmed: 33038342
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
Protein Sci. 1997 Aug;6(8):1771-3
pubmed: 9260291
Nat Immunol. 2016 Sep;17(9):1067-74
pubmed: 27455421
Immunity. 2005 Jul;23(1):29-40
pubmed: 16039577
Pharmaceutics. 2020 Mar 10;12(3):
pubmed: 32164343
Virology. 2014 Apr;454-455:371-9
pubmed: 24559861
J Immunol. 2007 Sep 1;179(5):2669-71
pubmed: 17709476
Int Immunol. 2001 Nov;13(11):1373-81
pubmed: 11675369
Mol Immunol. 2009 May;46(8-9):1911-7
pubmed: 19157553
J Exp Med. 1992 Jul 1;176(1):147-56
pubmed: 1613456
Mol Immunol. 2011 Jan;48(4):728-32
pubmed: 21130497
Nature. 1990 Aug 2;346(6283):476-80
pubmed: 2198471
Immunity. 2006 Oct;25(4):533-43
pubmed: 17046682
Immunity. 1995 Feb;2(2):137-47
pubmed: 7895170
J Immunol. 1998 May 1;160(9):4441-8
pubmed: 9574549
Eur J Immunol. 2012 Jun;42(6):1405-16
pubmed: 22678897
J Virol. 2006 Jun;80(12):6056-60
pubmed: 16731944
Immunogenetics. 1999 Nov;50(3-4):201-12
pubmed: 10602880
J Immunol. 1979 Jul;123(1):342-9
pubmed: 87477
Mol Cell. 2015 Dec 17;60(6):886-98
pubmed: 26698661
J Biol Chem. 2012 Nov 30;287(49):40867-74
pubmed: 23043111
J Immunol. 2016 Aug 15;197(4):1517-24
pubmed: 27402703
J Immunol. 2015 Jun 1;194(11):5329-45
pubmed: 25911754
J Pept Sci. 2016 Jan;22(1):4-27
pubmed: 26785684
Eur J Immunol. 2008 Feb;38(2):364-9
pubmed: 18196518
Science. 2019 May 3;364(6439):480-484
pubmed: 31048489
J Immunol Methods. 2016 May;432:95-101
pubmed: 26906089
Bioinformatics. 2011 Nov 1;27(21):2957-63
pubmed: 21903629
J Immunol. 2006 Oct 1;177(7):4699-708
pubmed: 16982909
Immunity. 2017 Feb 21;46(2):315-326
pubmed: 28228285
Nat Genet. 2017 Feb;49(2):193-203
pubmed: 27992415
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15812-7
pubmed: 14668432
J Immunol. 1989 May 1;142(9):3320-8
pubmed: 2785140
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Mol Cell Proteomics. 2015 Mar;14(3):658-73
pubmed: 25576301
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Trends Mol Med. 2001 Sep;7(9):379-81
pubmed: 11530315
Protein Pept Lett. 2002 Oct;9(5):379-85
pubmed: 12370025
PLoS One. 2019 Aug 8;14(8):e0220459
pubmed: 31393887
Immunity. 2000 Jan;12(1):83-93
pubmed: 10661408
FASEB J. 2015 Jul;29(7):2780-8
pubmed: 25782992
J Virol. 2009 Aug;83(15):7641-8
pubmed: 19458000
J Clin Invest. 2011 Jun;121(6):2480-92
pubmed: 21555856
Nat Immunol. 2009 Jun;10(6):636-46
pubmed: 19412183
J Virol. 2012 Nov;86(22):12013-24
pubmed: 22933291
PLoS Comput Biol. 2014 Feb 13;10(2):e1003478
pubmed: 24550723
BMC Immunol. 2008 Jan 22;9:1
pubmed: 18211710
J Immunol. 1996 May 1;156(9):3308-14
pubmed: 8617954
BMC Bioinformatics. 2009 Dec 15;10:421
pubmed: 20003500
J Immunol. 2008 Aug 1;181(3):2124-33
pubmed: 18641351
Physiol Genomics. 2003 Feb 06;12(3):221-8
pubmed: 12488511
Int J Pept Protein Res. 1991 Jun;37(6):513-20
pubmed: 1917309

Auteurs

Clarety Kaseke (C)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Ryan J Park (RJ)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Harvard Radiation Oncology Program, Boston, MA 02114, USA.

Nishant K Singh (NK)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

Dylan Koundakjian (D)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Arman Bashirova (A)

Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.

Wilfredo F Garcia Beltran (WF)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.

Overbeck C Takou Mbah (OC)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Jiaqi Ma (J)

Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN 46556, USA.

Fernando Senjobe (F)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Program in Virology, Harvard Medical School, Boston, MA 02114, USA.

Jonathan M Urbach (JM)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Anusha Nathan (A)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Elizabeth J Rossin (EJ)

Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA 02114, USA; The Broad Institute, Cambridge, MA 02142, USA.

Rhoda Tano-Menka (R)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Ashok Khatri (A)

Massachusetts General Hospital Endocrine Unit and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA.

Alicja Piechocka-Trocha (A)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

Michael T Waring (MT)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

Michael E Birnbaum (ME)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02142, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Brian M Baker (BM)

Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN 46556, USA.

Mary Carrington (M)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.

Bruce D Walker (BD)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; The Broad Institute, Cambridge, MA 02142, USA; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa; Institute for Medical Engineering and Science and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Gaurav D Gaiha (GD)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: ggaiha@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Allèles › HLA class-I-peptide stability mediates CD8
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › HLA class-I-peptide stability mediates CD8
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › HLA class-I-peptide stability mediates CD8
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › HLA class-I-peptide stability mediates CD8
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes d'histocompatibilité de classe I › HLA class-I-peptide stability mediates CD8
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › HLA class-I-peptide stability mediates CD8
questionsmedicales.fr › Facteurs biologiques › Antigènes › Épitopes › Épitopes immunodominants › HLA class-I-peptide stability mediates CD8
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › HLA class-I-peptide stability mediates CD8
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Pliage des protéines › Dépliement des protéines › Dénaturation des protéines › HLA class-I-peptide stability mediates CD8
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Stabilité protéique › HLA class-I-peptide stability mediates CD8
questionsmedicales.fr › Phénomènes chimiques › Propriétés de surface › HLA class-I-peptide stability mediates CD8